Literature DB >> 17003645

Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.

Mark Bloomston1, Tanios S Bekaii-Saab, Kavitha Kosuri, Sarah M Cowgill, W Scott Melvin, E Christopher Ellison, Peter Muscarella.   

Abstract

OBJECTIVES: Given the increased detection of occult pancreatic neoplasms with modern imaging modalities, it is often difficult to determine the risk of malignancy before curative pancreatectomy. We reviewed patients who underwent pancreatectomy to determine factors predictive of malignancy with particular attention to the serum marker carbohydrate antigen 19-9 (CA19-9).
METHODS: One hundred eighteen patients underwent radical pancreatectomy for malignant (n = 59) or benign (n = 59) pancreatic lesions. Demographic data, preoperative CA19-9 levels (normal, <37 U/mL), and follow-up were obtained from patient charts. Logistic regression analysis was used to determine univariate and multivariate predictors of malignancy.
RESULTS: Significant multivariate predictors of malignancy were increased CA19-9, age older than 50 years, and preoperative jaundice. The sensitivity and specificity of increased preoperative CA19-9 alone were 71% and 83%, respectively. The combination of age older than 50 years and jaundice was a more accurate predictor than CA19-9 (sensitivity, 76%; specificity, 92%). Increased CA19-9 was highly specific (97%) for malignancy in older jaundiced patients or when the preoperative level was greater than 150 U/mL.
CONCLUSIONS: Age and preoperative jaundice are more predictive of malignancy than CA19-9 alone unless levels are greater than 150 U/mL. Preoperative CA19-9 levels should be interpreted within the context of these other clinical factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003645     DOI: 10.1097/01.mpa.0000236726.34296.df

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  10 in total

1.  Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease.

Authors:  Sherif R Z Abdel-Misih; Ioannis Hatzaras; Carl Schmidt; Tanios-Bekaii Saab; Dori Klemanski; Peter Muscarella; W Scott Melvin; E Christopher Ellison; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2010-11-02       Impact factor: 5.344

2.  Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.

Authors:  Yun-Peng Zhao; Ping-Ting Zhou; Wei-Ping Ji; Hao Wang; Meng Fang; Meng-Meng Wang; Yue-Peng Yin; Gang Jin; Chun-Fang Gao
Journal:  Clin Exp Med       Date:  2015-12-29       Impact factor: 3.984

3.  Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms.

Authors:  Bin Xu; Wen-Yan Zheng; Da-Yong Jin; Wei-xing Ding; Wen-Hui Lou; Lajeswar Ramsohok
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

4.  Multimodality treatment of recurrent pancreatic cancer: Mith or reality?

Authors:  Cosimo Sperti; Lucia Moletta; Stefano Merigliano
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

5.  Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies.

Authors:  Ioannis Hatzaras; Carl Schmidt; Peter Muscarella; W Scott Melvin; E Christopher Ellison; Mark Bloomston
Journal:  HPB (Oxford)       Date:  2010-03       Impact factor: 3.647

Review 6.  Diagnosis and management of pancreatic cancer.

Authors:  A Collins; M Bloomston
Journal:  Minerva Gastroenterol Dietol       Date:  2009-12

Review 7.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

8.  CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent.

Authors:  Jonathan M Hernandez; Sarah M Cowgill; Sam Al-Saadi; Amy Collins; Sharona B Ross; Jennifer Cooper; Desireé Villadolid; Emmanuel Zervos; Alexander Rosemurgy
Journal:  J Gastrointest Surg       Date:  2008-10-30       Impact factor: 3.452

Review 9.  Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: a review.

Authors:  Sylvester N Osayi; Mark Bloomston; Carl M Schmidt; E Christopher Ellison; Peter Muscarella
Journal:  Biomed Res Int       Date:  2014-06-24       Impact factor: 3.411

10.  Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma.

Authors:  Qing-Long Deng; Shu Dong; Lei Wang; Chen-Yue Zhang; Hai-Feng Ying; Zhao-Shen Li; Xiao-Heng Shen; Yuan-Bao Guo; Zhi-Qiang Meng; Jin-Ming Yu; Qi-Wen Chen
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.